Jun 29, 2024, 14:51
Alessio Cortellini: Immune-suppressive role of RANKL in patients with NSCLC treated with ICI
Alessio Cortellini, Assistant Professor at Campus Bio-Medico University of Rome, shared a post by Journal for ImmunoTherapy of Cancer, on X:
“Happy to share this work out on Journal for ImmunoTherapy of Cancer on the potential immune-suppressive role of RANKL in patients with NSCLC treated with ICI. Entirely thought through and performed at UCBM.”.
Quoting Journal for ImmunoTherapy of Cancer‘s post:
“New JITC article: Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC).”
Read further.
Source: Alessio Cortellini/X and Journal for ImmunoTherapy of Cancer/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 13:07
Feb 21, 2025, 13:06
Feb 21, 2025, 13:03
Feb 21, 2025, 13:00
Feb 21, 2025, 12:53
Feb 21, 2025, 12:41
Feb 21, 2025, 12:39